Interview, Fireside Chat
Inside Moderna’s Biggest mRNA Test Since COVID
- The field anticipates the first successful cancer vaccine following over 20 years and more than 1,000 failed clinical trials, with Moderna and Merck scheduled to present data at an upcoming medical oncology conference.
- Regulatory filings are targeted to occur as soon as possible to enable patient availability by 2027, supported by a Massachusetts facility capable of scaling production for every human being and a Marlboro facility initially producing tens of thousands of doses.
- Phase three trials are ongoing for lung cancer, while phase two studies are active for kidney and bladder cancer, with a phase three monotherapy study for stage one lung cancer planned to begin in spring 2026.
- In pancreatic and gastric cancers where checkpoint inhibitors are ineffective, the company is testing vaccine combinations and expects to determine soon if the vaccine functions as a monotherapy in pancreas cancer, alongside anticipated benefits from a combination with Revolution Medicine's product.
- The strategy involves leveraging a mechanism of action orthogonal to checkpoint inhibitors like Keytruda to achieve synergy, with expectations of improvements versus Keytruda alone in studies where the latter is known to work.
- Efforts are directed toward addressing the 20% of non-responding patients through AI-driven analysis of phase three data to potentially upgrade the algorithm from version 1.0 to 2.0.
- Production efficiency targets include reducing the needle-to-needle cycle time, currently around 42 days, through automation and robotics, with potential construction of additional facilities required if production numbers continue to rise.
- The company plans to expand the technology platform to difficult-to-treat tumors and has identified autoimmune disease as the next focus following an announcement at the annual science day in June, aiming to treat root causes through individualized product and process approaches.
- Pivotal studies for rare genetic diseases of the liver are expected to conclude before the end of the year, while personalized cancer vaccines are positioned to be safer and easier than patient-manufactured alternatives.
- Continued learning is expected from the last decade of field advancements to improve the technology, with a long-term goal to understand the five-year response dynamics for non-responders.